დასაწყისი · კატალოგი · პროფილი · ცხრილი
სკრინინგი BODY HANDBOOK
სკრინინგი · §113
Annual Dilated Eye Exam for Diabetes
Diabetes silently damages the back of your eye long before you notice anything wrong. By the time vision blurs, the disease has often crossed the line where treatment salvages function rather than preserving it. The annual dilated eye exam — pupils widened with drops, full retina inspected — is the only practical way to catch the damage early enough that laser and anti-VEGF injections still keep your sight intact. The screen itself is cheap, well-covered by insurance, and decisively validated; the failure mode isn't the protocol, it's not showing up.
შეამოწმე · ყოველწლიურად მტკიცებულება ძლიერი თავი სკრინინგი

One yearly appointment, half a day of dilated vision afterward, and your eyes stay in the game. The treatments that prevent diabetic blindness — laser and injections refined across forty years of clinical trials — only work when the damage is caught while sight is still intact. About 40% of US adults with diabetes miss the exam each year, and diabetic retinopathy stays the leading cause of working-age blindness in countries that haven't built screening into the system.

Chronic high blood sugar punches small holes in the tiniest blood vessels at the back of your eye. The damage starts at the periphery — the part of the retina you don't actually see with — so for years it produces no symptoms. By the time it reaches the central retina that you read and drive with, it's usually because the disease has hit a much later stage: fluid building up under the macula, bleeding into the clear gel inside the eye, or scar tissue pulling the retina off the back wall. Those late stages are still treatable, but treatment works far better when the damage gets caught earlier.

Dilation is the whole point. The drops widen your pupils enough that the clinician can look past the central retina out to the periphery, where the early signs sit. Without dilation, the small pupil only shows the back wall straight on, and roughly half of clinically meaningful disease gets missed (Flaxel et al., AAO Preferred Practice Pattern 2020). A vision check for glasses is not a dilated retinal exam — same chair, different procedure.

Why we know this works

Three decades of treatment trials sit behind the screen. Panretinal laser cuts the rate of severe vision loss in the most advanced stage of retinopathy by about half (Diabetic Retinopathy Study Group 1981). A different laser pattern cuts moderate vision loss from central retinal swelling by about half (ETDRS Report 9, 1991). Anti-VEGF injections given every month or two produce average gains of nine to thirteen letters on a standard reading chart in patients whose macula has started leaking (Wells et al., NEJM 2015).

These treatments share a property: they all work much better when the damage is caught earlier. A patient detected at the mild-changes stage and treated when warranted keeps their driving and reading vision into older age. A patient who walks in already bleeding into the eye gets a treatment that may stabilize them but rarely restores what was lost.

What happens if you stop showing up

Anchor on the typical case: type 2 diabetes, sugars not quite where they should be, busy. The skipped exams compound quietly.

Year one of not going: nothing. Vision stays sharp. Your eyes look fine in the mirror.

Year three: a thread or a smudge crosses your view once in a while, and you blink it away and forget. What you don't see is the fine layer of fluid that has started collecting under your macula, or the new fragile vessels growing on the surface of the retina that aren't supposed to be there at all.

Year five: you start holding your phone closer to read it, and you assume your glasses prescription drifted. When you finally end up in an eye chair for a different reason and the clinician puts drops in, they go quiet. The bleed has already happened. The treatment you would have gotten three years ago — focal laser, a handful of injections, done — gets traded for chronic monthly injections indefinitely, and you keep most but not all of what you had.

What that "most but not all" looks like in a life: you stop driving at night. Reading takes magnifiers. The depression rate roughly triples in people with significant visual impairment compared to sighted peers — not because vision loss is uniquely terrible, but because the things you used to do for fun get a little harder, and over a year that adds up. Fall risk rises with it. None of this is dramatic, but it changes the shape of your sixties and seventies.

The extreme version is more dramatic and less common: a sudden vitreous hemorrhage where you wake up one morning and one eye is curtained, or a retinal detachment that needs surgery within days. Both happen. Diabetic retinopathy was the leading cause of new blindness certifications in working-age adults in England before universal screening shifted the curve (Liew et al. 2014). The intervention that moved the curve was not new treatment — the treatments existed — but more people getting seen at a stage when those treatments could still work.

How the screen works

The cadence is the same across every major guideline (ADA Standards of Care 2024), (AAO Preferred Practice Pattern 2020), (ICO 2018):

  • Type 2 diabetes: a first dilated exam at the time of diagnosis (because the disease has often been there silently for years before diagnosis), then yearly.
  • Type 1 diabetes: a first exam within five years of diagnosis, then yearly.
  • Pregnancy with pre-existing diabetes: exam before conception or in the first trimester, then every one to three months through the pregnancy and into the first year after.

The visit itself runs about 45 to 90 minutes. The clinician puts dilating drops in both eyes, you wait around 30 minutes for them to take full effect, and then a slit lamp and a head-mounted scope let them see the entire retina. Many offices also take a photograph of the back of each eye for the record. You leave with your pupils still wide, light feels too bright for four to six hours, and near vision stays blurry for that same window.

What most people get wrong

Three lines come up almost every time:

I can see fine, so my eyes are fine. The whole reason the screen exists is that early diabetic retinopathy doesn't hurt and doesn't blur. Central vision stays sharp until the disease either floods the macula with fluid or bleeds into the gel inside the eye. By the time the felt change shows up, the easy window is gone.

My regular eye exam covers it. A refraction for glasses, even at the same office on the same chair, is not a dilated retinal exam. The dilation, the inspection of the periphery, and the billing are all separate. Many routine vision exams skip the drops entirely — if you haven't been asked to wait 30 minutes for your pupils to widen, you probably didn't get screened.

My A1c is good, so I don't need it. Tight glucose control cuts retinopathy risk by 54–76% over a decade (DCCT 1993), but it doesn't drive the rate to zero. The long-running Wisconsin cohort found 97% of type 1 patients develop some retinopathy and 43% reach the proliferative late stage by 25 years of disease duration (Klein et al. 2008). Good control buys time. It doesn't replace the screen.

If a clinic dilated exam isn't practical

Two evidence-backed alternatives when access — distance, transport, time off work — is the real bottleneck.

The first is telemedicine retinal photography. A digital camera in your primary care office takes pictures of your retinas (sometimes without dilation, sometimes with), and a remote grader or ophthalmologist reads them. This is how the English National Screening Programme runs at population scale; the ADA explicitly endorses validated telemedicine programs as a substitute for the in-person dilated exam (ADA 2024), (Scanlon 2017).

The second is autonomous AI screening. The IDx-DR system — now called LumineticsCore — was the first AI tool the FDA authorized to make a clinical diagnosis without a doctor in the loop. In its pivotal trial it caught 87% sensitivity for more-than-mild retinopathy with 91% specificity, deployed point-of-care in primary clinics (Abramoff et al. 2018). Coverage is expanding; ask your primary care office whether they have it.

What does not substitute: glucose control alone (necessary, not sufficient), watching your own vision at home (only flags problems once they hit the central retina, which is already late), or an in-office eye exam without pupil dilation.

What an unbroken annual rhythm buys

The unglamorous version is most of what happens. You show up, the doctor looks, nothing's there, you wait a year. Eight years in a row of that, and your vision over the long run looks like a non-diabetic person's vision over the long run. You keep driving at night. You keep reading without leaning in. And the appointment quietly does double duty: the same dilated look is where open-angle glaucoma — the other disease that steals sight without ever announcing itself — usually gets caught first.

The version where the screen earns its keep: in any given year, roughly one in twenty patients with long-duration diabetes is found to have something that warrants treatment or closer monitoring. If that turns out to be you, the conversation happens early. The retinal specialist explains what's there, what to do about it, and the trajectory you're now on — which is the one where the treatments work as intended.

The population-level version is the cleanest evidence the catalogue has for the screen's value. In the United Kingdom, where systematic photography-based screening reaches the bulk of diabetic adults annually, diabetic retinopathy was knocked out of the top spot for working-age blindness for the first time in at least five decades (Liew et al. 2014). Your annual exam is one row of that table.

Adjacent practices that share the same diabetic-care infrastructure: tight glycemic control (the upstream risk factor for everything in the eye), blood pressure management (the other major retinopathy modifier), the annual diabetic foot exam (parallel screening, parallel evidence base), urine microalbumin testing for diabetic kidney disease. Each gets its own attention; the annual eye exam is the visual layer of a broader complications-prevention rhythm.

დაკავშირებული სახელმძღვანელოში
დაკავშირებული
  • — The eye exam catches the damage; tight glucose control is what prevents it. A monitor shows you the spikes that quietly harm the retina.
  • — The same dilated exam that screens for diabetic eye damage is where open-angle glaucoma usually gets caught too.
  • — The yearly diabetic eye exam starts at diagnosis; damage can already be underway in the first 90 days.
  • — Between yearly exams, a home Amsler grid can flag new macular swelling early. Wavy lines mean call sooner, not later.
  • — Different trigger, same idea: diabetes means yearly dilated exams regardless of age.
  • — How fast the eye damage builds tracks your long-run blood sugar — which the A1c estimates, imperfectly.
  • — Between annual exams, sudden floaters, shadows or vision loss mean don't wait for the next appointment.
  • — Eyes and kidneys take diabetic damage in parallel — the yearly eye exam has a kidney-screen counterpart.
·
113